Search hospitals > Illinois > Orland Park
University of Chicago Medicine-Orland Park
Claim this profileOrland Park, Illinois 60462
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Breast Cancer
Conducts research for Tumors
Conducts research for Adenocarcinoma
110 reported clinical trials
26 medical researchers
Summary
University of Chicago Medicine-Orland Park is a medical facility located in Orland Park, Illinois. This center is recognized for care of Cancer, Recurrence, Breast Cancer, Tumors, Adenocarcinoma and other specialties. University of Chicago Medicine-Orland Park is involved with conducting 110 clinical trials across 293 conditions. There are 26 research doctors associated with this hospital, such as Rita Nanda, MD, Ardaman Shergill, MD, Christine M. Bestvina, and John Moroney, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Recurrence
Global LeaderStage IV
Stage III
Stage I
Top PIs
Rita Nanda, MDUniversity of Chicago Comprehensive Cancer Center7 years of reported clinical research
Expert in Breast Cancer
Studies Cancer
24 reported clinical trials
47 drugs studied
Ardaman Shergill, MDUniversity of Chicago Comprehensive Cancer Center3 years of reported clinical research
Studies Colorectal Cancer
Studies Adenocarcinoma
23 reported clinical trials
61 drugs studied
Christine M. BestvinaUniversity of Chicago Comprehensive Cancer Center5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
18 reported clinical trials
33 drugs studied
John Moroney, MDUniversity of Chicago4 years of reported clinical research
Expert in Ovarian Cancer
Studies Ovarian Tumors
16 reported clinical trials
37 drugs studied
Clinical Trials running at University of Chicago Medicine-Orland Park
Breast Cancer
Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Renal Cell Carcinoma
Bladder Carcinoma
Bladder Cancer
Diffuse Large B-Cell Lymphoma
Gallbladder Cancer
Omitting Radiation Therapy
for Breast Cancer
This study is evaluating whether a type of radiation therapy may help prevent breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Chicago Medicine-Orland Park?
University of Chicago Medicine-Orland Park is a medical facility located in Orland Park, Illinois. This center is recognized for care of Cancer, Recurrence, Breast Cancer, Tumors, Adenocarcinoma and other specialties. University of Chicago Medicine-Orland Park is involved with conducting 110 clinical trials across 293 conditions. There are 26 research doctors associated with this hospital, such as Rita Nanda, MD, Ardaman Shergill, MD, Christine M. Bestvina, and John Moroney, MD.